Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
The ReBuilder(R) is an electronic device that restores nerve function,increases blood flow, cancels pain, and reduces numbness and tingling thatsells for $399-$699 retail and is available on the Internet and throughselective physician's offices.
Advertisement
"We are pleased to add Mr. Evans to our team," says Adeyemi Bandele, VPReBuilder Medical, Inc. "We have recently ramped up our production by a factorof three and we have outgrown our manual, paper related based quality controlprocedures. Although we have classically had more than a 99% pass rate, at thelevels of production we now have, and the growth we expect to achieve in thecoming months as a result of our expanded marketing efforts, we needed a new,systematic, computerized system to ensure that we maintain our product qualityas strong as ever."
ReBuilder Medical Technologies, Inc. invented, developed, and holds theintellectual property rights to the ReBuilder System(R) for diabeticperipheral neuropathy and the technology to produce micronized amorphoussilver ions for diabetic personal hygiene products. According to the AmericanDiabetes Association, there are over 20 million people in the US sufferingwith diabetes and 30% of these patients will eventually develop the pain,numbness and loss of mobility that accompany diabetic peripheral neuropathy.The overall total economic cost of diabetes is over $132 billion. One ofevery 10 dollars spent on health costs in America is spent on diabetes. Withthe graying of the baby boomers, these numbers are expected to climb.
In the coming months ReBuilder Medical will be seeking additional staffingfrom the pool of retired execs in the community.
According to David Phillips, CEO of ReBuilder Medical Technologies, Inc.,the target for the retired executives program is to have the retirees reducecustomer queries concerning product quality by 50 percent. This reductionshould reduce salaries spent on customer service inquiries as well.
"From a financial point of view," says Daena Carter, Director ofAccounting for ReBuilder Medical Technologies, Inc., "recruiting retiredexecutives from the community makes good sense. They come with an establishedwork ethic, and appreciate the opportunity to still make a contribution. Weappreciate them and can accommodate their needs for time off for personalissues relating to health and family."
Twenty million, eight hundred thousand children and adults, or 7% of theU.S. population suffer from diabetes. Thirty percent of those diagnosed withdiabetes will eventually suffer from peripheral neuropathy, pain and numbnessin the feet and hands that can lead to complete loss of mobility, gangrene,and eventual amputations. $132 Billion per year is the current cost oftreating diabetes, or 1 of every 10 health care dollars spent. Neuropathysufferers constitute 33% of this market, or 43.56 billion dollars in potentialmarket. ReBuilder Medical Technologies, Inc. is a company in its infancy thathas targeted 1% of this market, or, $43.5 million dollars in its next twomarket years, and is on course to meet this goal. Its primary competition isfrom drug companies whose drug therapy has proven less successful and prone tonegative side-effects and addiction.
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is an emerging medical devicemanufacturer of innovative technologies founded by world renowned medicaldevice inventor David B. Phillips, Ph.D. ReBuilder Medical's fl
